-49%

est. 2Y upside i

HealthcareSeries B

Rank

#455

Sector

Healthtech

Est. Liquidity

~3Y

Data Quality

Data: Low

House Rx operates in a massive and rapidly expanding specialty pharmacy market, with its AI-enabled platform and clinic-integrated model well-positioned to capitalize on regulatory tailwinds against traditional PBMs.

Last updated: March 10, 2026

Bull (27%)+300%

House Rx achieves significant market penetration, leveraging its AI-enabled platform and favorable regulatory environment to capture substantial share from traditional PBMs. Revenue exceeds $105M by 2028, justifying a premium valuation of $1.6B, representing a +300% upside.

Base (41%)+130%

House Rx maintains its strong growth trajectory, expanding its network to ~150 clinic sites and achieving ~$92M in annual revenue by 2028. This growth, coupled with its differentiated AI-powered platform, justifies a valuation of approximately $920M, representing a +130% upside from the current Series B valuation.

Bear (32%)-50%

Dominant PBMs intensify competition by launching similar in-clinic solutions or leveraging their existing networks, leading to slower-than-expected growth for House Rx. Revenue growth stalls, and the company faces a down round or struggles to raise further capital, resulting in a valuation of $200M, a -50% downside from the current valuation. Given the $100M preference stack, common stock value would be significantly impaired.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors have contributed $100M, which would typically be senior to common stock. In an exit at or below the $400M Series B valuation, common shareholders would receive significantly less, potentially nothing if the exit is below $100M.

Dilution Risk

moderate

With $100M raised to date, and likely needing more capital to scale, future equity rounds will dilute existing shareholders, including employees.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for House Rx equity at this stage.

View all 19 open roles at House Rx →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on House Rx's data — designed to show you've done your homework.

  • 1

    “Given the dominance of large PBMs in the specialty pharmacy market, how does House Rx plan to further differentiate its offering and overcome potential competitive responses from these incumbents, especially as they face increasing regulatory scrutiny?”

  • 2

    “The company is processing $1.5 billion in specialty scripts annually, projected to reach $3 billion by 2026. How does this translate into revenue growth, and what are the key drivers for converting this volume into sustainable, high-margin software and service revenue?”

  • 3

    “With $100M in total funding and a recent Series B, what is the anticipated timeline for a liquidity event (e.g., IPO or acquisition), and how is the company thinking about managing potential future dilution and providing liquidity for employees?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.